ReviewTheScientificWorldJournal2011
Tracheobronchial manifestations of Aspergillus infections.
Review in TheScientificWorldJournal, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed, 1 synthesis or guideline pooled it, 86 citations in OpenAlex.
- Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2016Guideline
- Invasive Necrotizing Tracheobronchial Aspergillosis in Children: A Case Series and Literature Review.The American journal of case reports · 2026Review
- Invasive Aspergillus Tracheobronchitis Presenting as Subglottic Stenosis: A Case Report.Respirology case reports · 2026Article
- Tracheobronchial Aspergillosis Mimicking Pseudotumoral Lesions in a Rare Presentation of a Known Disease.Clinical case reports · 2025Article
- Tracheobronchial Wall Thickening in a Patient With Inflammatory Bowel Disease.CHEST pulmonary · 2025Article
- Pulmonary Aspergillosis in Immunocompromised Critically Ill Patients: Prevalence, Risk Factors, Clinical Features and Diagnosis-A Narrative Review.Journal of fungi (Basel, Switzerland) · 2025Review
- Impact of CD11cFrontiers in fungal biology · 2025Article
- A Case Report of COVID-19 With Tracheobronchial Aspergillosis.Case reports in infectious diseases · 2025Article
- Case report: A special case of pneumonia with a novel STAT3 mutation and Talaromyces marneffei infection.Respiratory medicine case reports · 2025Article
- Article
- Aspergillus and the Lung.Seminars in respiratory and critical care medicine · 2024Review
- Severe pulmonary aspergillosis post viral illness in immunocompetent patients: A case series.Respiratory medicine case reports · 2024Article
- Clinical Uses of Inhaled Antifungals for Invasive Pulmonary Fungal Disease: Promises and Challenges.Journal of fungi (Basel, Switzerland) · 2023Review
- Successful treatment of invasive tracheobronchial pulmonary aspergillosis with venovenous extracorporeal membrane oxygenation and combined systemic, intratracheal instillation of liposomal amphotericin B: a case report.Journal of medical case reports · 2022Article
- Aspergillus tracheobronchitis with Birt-Hogg-Dubè syndrome as a rare cause of chronic cough.BMC pulmonary medicine · 2022Article
- Potential Antifungal Targets forInternational journal of molecular sciences · 2022Review
- Fungal infections in lung transplantation.Journal of thoracic disease · 2021Review
- Differences in Clinical Characteristics of Invasive Tracheobronchial Aspergillosis according to the Presence of Invasive Pulmonary Aspergillosis.Tuberculosis and respiratory diseases · 2021Article
- Characteristics of the Computed Tomography Imaging Findings in 72 Patients with Airway-Invasive Pulmonary Aspergillosis.Medical science monitor : international medical journal of experimental and clinical research · 2021Article
- Aspergillus Niger-pulmonary Aspergillosis in an Immunocompetent Woman.Internal medicine (Tokyo, Japan) · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Human lungs are constantly exposed to a large number of Aspergillus spores which are present in ambient air. These spores are usually harmless to immunocompetent subjects but can produce a symptomatic disease in patients with impaired antifungal defense. In a small percentage of patients, the trachea and bronchi may be the main or even the sole site of Aspergillus infection. The clinical entities that may develop in tracheobronchial location include saprophytic, allergic and invasive diseases. Although this review is focused on invasive Aspergillus tracheobronchial infections, some aspects of allergic and saprophytic tracheobronchial diseases are also discussed in order to present the whole spectrum of tracheobronchial aspergillosis. To be consistent with clinical practice, an approach basing on specific conditions predisposing to invasive Aspergillus tracheobronchial infections is used to present the differences in the clinical course and prognosis of these infections. Thus, invasive or potentially invasive Aspergillus airway diseases are discussed separately in three groups of patients: (1) lung transplant recipients, (2) highly immunocompromised patients with hematologic malignancies and/or patients undergoing hematopoietic stem cell transplantation, and (3) the remaining, less severely immunocompromised patients or even immunocompetent subjects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.